Downloadable Resources

For additional resources—start here
Expert Videos
ROS1 Is Real Video Series
Watch expert oncologists and patients discuss the importance of identifying ROS1-positive metastatic NSCLC through biomarker testing, selecting an initial treatment, and treating with XALKORI.
Click on the play button below to view the full video or the links to the right to see individual chapters.
*Preferred interventions are based on efficacy, safety, and evidence. Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate. All NCCN recommendations are category 2A unless otherwise indicated.
The NCCN Guidelines® for NSCLC provide recommendations for individual biomarkers that should be tested and recommend testing techniques but do not endorse any specific commercially available biomarker assays.
ALK=anaplastic lymphoma kinase; EGFR=epidermal growth factor receptor; NSCLC=non-small cell lung cancer.
REFERENCE
  1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.3.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed January 18, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.